Komodo Health and ZERO Prostate Cancer Announce Partnership to Close Gaps in Prostate Cancer Screening and Care

Prostate cancer is the second-leading cause of cancer death among American men (about 333,830 new cases and 36,320 deaths projected for 2026); screening pattern shifts have caused incidence to rise again after years of decline while mortality-rate gains have slowed, with significant racial and economic disparities affecting Black men, veterans and underserved rural communities. Komodo Health and ZERO Prostate Cancer partnered, using Komodo's AI platform and Healthcare Map (330+ million de-identified patient journeys) to support ZERO's "Blitz the Barriers" initiative, giving real-time visibility into patient journeys, screening gaps and care-pathway breakdowns. After a successful 2025 Atlanta pilot, the program is expanding to Baltimore, Washington D.C., New Orleans, Detroit and Houston with support from Novartis and other partners, aiming to save 100,000 lives by 2035.

Komodo Health runs the 'Healthcare Map,' one of the largest linked longitudinal patient-record graphs sold commercially into pharma for real-world analytics.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.